Advanced proteomic biomarker discovery for understanding disease pathophysiology
Join Dr. Eric Schordan, Chief Scientific Officer at Firalis Molecular Precision, and Dr. Kamila Koprowska, Senior Business Development Scientist at SPT Labtech, as they explore the transformation of large-scale proteomic data generation using the Olink® Explore platform integrated with positive displacement liquid handling technology.
Learn how this combination enables deeper insights into the physiopathologic mechanisms underlying various drugs and diseases by providing a comprehensive readout of protein expression levels in biological samples. The session will feature case studies demonstrating how robust and precise automation supports high-throughput multiomics research with minimal sample volumes.
Key learning objectives
- Gain insights into next-generation proteomics
- Learn how to identify critical biomarkers for diagnostic, prognostic, and monitoring purposes
- Find out more about data integration
Who should attend?
Researchers from pharmaceutical and biotech industries, as well as academia, who are interested in proteomics and multiomics.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Speakers
Dr. Eric Schordan has over 14 years of experience in various roles within the biotechnology and diagnostics industry. He is currently working as Lab Director for CAP accredited tests at Firalis Molecular Precision, a laboratory in France accredited by the College of American Pathologists. He also serves as the Chief Scientific Officer, where he is involved in product and biomarker development strategies, customer relations, and process improvement.
Dr. Kamila Koprowska is the Product Manager for the mosquito® range of liquid handlers at SPT Labtech. In recent years, her focus has been on partnering with application leaders worldwide to co-create solutions that tackle new challenges in life sciences and push the boundaries of what is possible. She has an M.Eng. in Biotechnology and a PhD in Medical Biology. She completed her academic training with a post-doctoral position at the Cancer and Immunogenetics Laboratory, MRC Weatherall Institute of Molecular Medicine in Oxford, UK.
Moderator
